ASCO: Amgen takes victory lap as Imdelltra prolongs life in small cell lung cancer
The T-cell engager has shown that it can help patients live longer, has a more tolerable safety profile and improves certain cancer-related symptoms compared with chemotherapy in second-line small cell lung cancer.
The T-cell engager has shown that it can help patients live longer, has a more tolerable safety profile and improves certain cancer-related symptoms compared with chemotherapy in second-line small cell lung cancer.
